|
 |
European BioPharmaceutical Review
|
| It is only over the last 25 years that osteoporosis, the most common bone metabolism disease, has been the subject of in-depth research. Osteoporosis (bone loss) is characterised by reduced bone mass and a disruption in the microarchitecture of the bone tissue. Healthy bone is in a state of constant turnover, the bone being broken down and reformed. This process is controlled by the sex hormones oestrogen and testosterone. If bone mass is to be preserved, a long-term balance must be maintained between bone formation (osteoblast activity) and bone breakdown or resorption (osteoclast activity). In osteoporosis this balance is disrupted and excessive loss of bone mass occurs, resulting in increased bone fragility and a greater susceptibility to fractures. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EuroBiopartnering 2008
7-9 October 2008, Paris, France
EuroBiOpartnering
2008 gives you the unique opportunity to meet the relevant decision makers and
opinion leaders from the international biotech community and offers you 3 days
of partnering opportunities including one-to-one meetings, company presentations
and further networking activities…
More info >> |
|
 |
News and Press Releases |
 |
Vindon Scientific on the Move
More info >> |
|
 |
